MapLight Therapeutics, Inc.
MPLTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, MapLight Therapeutics, Inc. focuses on Biotechnology services and products. MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The $442.9M market capitalization puts MPLT squarely in small-cap range for its industry. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders.
Market Cap
$442.9M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-2.33
EPS (TTM)
$-6.25
EPS (Fwd)
$-3.42
ROE
-111.5%
ROA
-67.1%
Cash
$304.7M
Total Debt
$2.0M
Free CF
-$95.2M
52W Change
-56.5%
Annual Financials
Cash vs Debt
Where MPLT stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, MPLT finished 63.60% below its 150-day moving average ($21.98) and 61.81% below its 200-day moving average ($20.95). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MPLT overbought or oversold?
At the October 20, 2026 close, MPLT's RSI(14) was 25.9, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $304.7M in cash and $2.0M in debt, MPLT maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$95.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -111.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, MPLT has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing MPLT.